Inhibition of MDM2 attenuates neointimal hyperplasia via suppression of vascular proliferation and inflammation

Cardiovascular Research

Volumn 91, Issue 4, 2011, Pages 711-719

  Hashimoto, Toru ^a   Ichiki, Toshihiro ^a   Ikeda, Jiro ^a   Narabayashi, Eriko ^a   Matsuura, Hirohide ^a   Miyazaki, Ryohei ^a   Inanaga, Keita ^b   Takeda, Kotaro ^a   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Kyushu University Graduate School of Medical Sciences ^*

Author keywords

Inflammation; MDM2; Neointima; p53; Proliferation

Indexed keywords

BROXURIDINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MESSENGER RNA; NUTLIN 3; PLATELET DERIVED GROWTH FACTOR; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RANTES; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; FLOW CYTOMETRY; GENETIC TRANSFECTION; HYPERPLASIA; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; HYPERPLASIA; IMIDAZOLES; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; NEOINTIMA; NF-KAPPA B; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; RATS; RATS, SPRAGUE-DAWLEY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80051971299     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr108     Document Type: Article

References (41)

1. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874. (Pubitemid 36019640)
2. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 2002;8:1249-1256. (Pubitemid 35373556)
3. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005;111:2257-2273. (Pubitemid 40632443)
4. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-412. (Pubitemid 351574202)
5. Guevara NV, Kim HS, Antonova EI, Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med 1999;5:335-339. (Pubitemid 29124372)
6. van Vlijmen BJ, Gerritsen G, Franken AL, Boesten LS, Kockx MM, Gijbels MJ et al. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ Res 2001;88:780-786. (Pubitemid 32429973)
7. Merched AJ, Williams E, Chan L. Macrophage-specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling. Arterioscler Thromb Vasc Biol 2003;23:1608-1614. (Pubitemid 37108205)
8. Mercer J, Figg N, Stoneman V, Braganza D, Bennett MR. Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. Circ Res 2005;96:667-674. (Pubitemid 40478334)
9. von der Thüsen JH, van Vlijmen BJ, Hoeben RC, Kockx MM, Havekes LM, van Berkel TJ et al. Induction of atherosclerotic plaque rupture in apolipoprotein E2/2 mice after adenovirus-mediated transfer of p53. Circulation 2002;105:2064-2070. (Pubitemid 34465269)
10. Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 2007;39:1476-1482. (Pubitemid 47031042)
11. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006;6:909-923. (Pubitemid 44862676)
12. Ihling C, Haendeler J, Menzel G, Hess RD, Fraedrich G, Schaefer HE et al. Co-expression of p53 and MDM2 in human atherosclerosis: implications for the regulation of cellularity of atherosclerotic lesions. J Pathol 1998;185:303-312. (Pubitemid 28320053)
13. Nakamura Y, Suzuki S, Suzuki T, Ono K, Miura I, Satoh F et al. MDM2: a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling. Am J Pathol 2006;169:362-371. (Pubitemid 44156299)
14. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303: 844-848. (Pubitemid 38174664)
15. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007;13:23-31. (Pubitemid 46027725)
16. Sarek G, Kurki S, Enback J, Iotzova G, Haas J, Laakkonen P et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest 2007; 117:1019-1028. (Pubitemid 46556758)
17. Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L et al. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst 2009;101:1562-1574.
18. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006;103:1888-1893. (Pubitemid 43228788)
19. Endo S, Yamato K, Hirai S, Moriwaki T, Fukuda K, Suzuki H et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci 2011;102:605-613.
20. Sata M, Maejima Y, Adachi F, Fukino K, Saiura A, Sugiura S et al. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol 2000;32:2097-2104.
21. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-1312. (Pubitemid 351717519)
22. de Winther MP, Kanters E, Kraal G, Hofker MH. Nuclear factor kB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 2005;25:904-914.
23. Liu G, Park YJ, Tsuruta Y, Lorne E, Abraham E. p53 Attenuates lipopolysaccharide-induced NF-kB activation and acute lung injury. J Immunol 2009; 182:5063-5071.
24. Dey A, Wong ET, Bist P, Tergaonkar V, Lane DP. Nutlin-3 inhibits the NFkB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle 2007;6: 2178-2185. (Pubitemid 47450420)
25. Secchiero P, Corallini F, Rimondi E, Chiaruttini C, di Iasio MG, Rustighi A et al. Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. Blood 2008;111:1287-1294. (Pubitemid 351213412)
26. Wadgaonkar R, Phelps KM, Haque Z, Williams AJ, Silverman ES, Collins T. CREBbinding protein is a nuclear integrator of nuclear factor-kB and p53 signaling. J Biol Chem 1999;274:1879-1882.
27. Webster GA, Perkins ND. Transcriptional cross talk between NF-kB and p53. Mol Cell Biol 1999;19:3485-3495. (Pubitemid 29193808)
28. Yonemitsu Y, Kaneda Y, Tanaka S, Nakashima Y, Komori K, Sugimachi K et al. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ Res 1998;82:147-156. (Pubitemid 28080097)
29. Matsushita H, Morishita R, Aoki M, Tomita N, Taniyama Y, Nakagami H et al. Transfection of antisense p53 tumor suppressor gene oligodeoxynucleotides into rat carotid artery results in abnormal growth of vascular smooth muscle cells. Circulation 2000;101:1447-1452. (Pubitemid 30169869)
30. George SJ, Angelini GD, Capogrossi MC, Baker AH. Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. Gene Ther 2001;8:668-676. (Pubitemid 32499226)
31. Mayr U, Mayr M, Li C,Wernig F, Dietrich H, Hu Y et al. Loss of p53 accelerates neointimal lesions of vein bypass grafts in mice. Circ Res 2002;90:197-204. (Pubitemid 34627089)
32. Sata M, Tanaka K, Ishizaka N, Hirata Y, Nagai R. Absence of p53 leads to accelerated neointimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol 2003;23: 1548-1552. (Pubitemid 37108196)
33. Wan S, George SJ, Nicklin SA, Yim AP, Baker AH. Overexpression of p53 increases lumen size and blocks neointima formation in porcine interposition vein grafts. Mol Ther 2004;9:689-698. (Pubitemid 38660422)
34. Sanz-González SM, Barquín L, García-Cao I, Roque M, González JM, Fuster JJ et al. Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis. Cardiovasc Res 2007;75:803-812. (Pubitemid 47238733)
35. Aylon Y, Oren M. Living with p53, dying of p53. Cell 2007;130:597-600. (Pubitemid 47268063)
36. Secchiero P, Corallini F, Gonelli A, Dell'Eva R, Vitale M, Capitani S et al. Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 2007;100:61-69. (Pubitemid 46066774)
37. Perlman H, Maillard L, Krasinski K,Walsh K. Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. Circulation 1997;95:981-987. (Pubitemid 27091544)
38. Moran DM, Maki CG. Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Mol Cancer Ther 2010;9: 895-905.
39. Gadea G, Lapasset L, Gauthier-Rouviere C, Roux P. Regulation of Cdc42-mediated morphological effects: a novel function for p53. Embo J 2002;21:2373-2382. (Pubitemid 34546710)
40. Guo F, Gao Y, Wang L, Zheng Y. p19Arf-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities. J Biol Chem 2003;278:14414-14419. (Pubitemid 36799994)
41. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr., Kinzler KW et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 2009;106:3964-3969.